Veraxa Biotech Holding AG

Veraxa Biotech AG filed an F-1 registration statement for the resale of up to 19,436,739 Ordinary Shares underlying warrants and up to 6,786,739 Private Warrants. Additionally, the filing covers up to 120,295,385 Ordinary Shares held by selling securityholders, including those from the recent Business Combination, Cantor Fitzgerald, and High Trail financing. The company also secured a $27.5 million Senior Secured Note from High Trail and entered a purchase agreement with Lincoln Park for up to $50 million in future share sales.

Veraxa Biotech AG announced significant updates to its core patent portfolio, including the filing of new applications for its BiTAC-TCE and BiTAC-ADC platforms in H1 2026. The company now holds over 50 granted patents across 26 families in 14 countries, with new applications expected to extend protection through at least 2047. This expansion aims to safeguard its innovative technologies, including click chemistry and conjugation, for next-generation cancer therapies.

Veraxa Biotech AG announced the advancement of its novel bispecific antibody drug conjugate (bsADC) program VXA-222. This follows the successful achievement of a key technical milestone in its alliance with OmniAb, Inc., with OmniAb's discovery work now concluded. VXA-222 employs an "AND-gate" logic to address two different target antigens present on solid tumors, representing a significant step in developing next-generation cancer therapies.

VERAXA Biotech AG shareholders overwhelmingly approved all proposals at an Extraordinary General Meeting, granting the company enhanced corporate and financing flexibility. Key approvals include conditional share capital for options and warrants, a capital band until 2030, and an increase in the maximum Board of Directors members. Additionally, the company announced the initiation of cell line development with ATUM for its lead BiTAC®-TCE program, a crucial step towards clinical development for its next-generation cancer therapeutics.

Veraxa Biotech AG announced the appointment of Christoph Erkel, Ph.D., as its new Chief Scientific Officer, effective immediately. Dr. Erkel, previously the company's Vice President of Research & Development, will lead the acceleration of Veraxa's proprietary BiTAC® platform technologies to develop advanced cancer treatments. He brings 20 years of experience in antibody therapeutics and succeeds Rick Austin, Ph.D., who is departing the company.

Veraxa Biotech AG announced it received positive Scientific Advice from the German regulatory authority, the Paul-Ehrlich-Institute (PEI), regarding its BiTAC-TCE technology. The advice focused on the underlying biology and proposed non-clinical development plan for its most advanced program. This supportive feedback validates the biological concept and provides greater clarity, derisking the development path for the novel cancer therapy. Initial data presented at AACR 2026 demonstrated superior safety and matching efficacy for the BiTAC-TCE candidate.

Veraxa Biotech announced a collaboration with Ardigen S.A., an AI-driven computational partner, to integrate artificial intelligence into its research and development. This partnership will support Veraxa's growing BiTAC® pipeline of T-cell engagers and antibody-drug conjugates by developing AI-enabled tools to guide the selection of synergistic cancer target pairs. The goal is to overcome limitations of current high-potency modalities, such as on-target, off-tumor toxicities, and achieve drug development success rates that exceed industry benchmarks.

Veraxa Biotech Holding AG announced the appointment of Carl von Halem as Interim Chief Financial Officer, succeeding Torsten Bürgermeister. Mr. von Halem, who previously served as CFO of Xlife Sciences and was instrumental in VERAXA's IPO, brings extensive experience in corporate finance and the life sciences sector. The company is actively seeking a permanent CFO to support its next phase of expansion and operational growth.

Veraxa Biotech AG provided a company and pipeline update, highlighting substantial progress in the first half of 2026. The company is prioritizing its novel BiTAC technology, expecting it to be the main value driver, and plans to channel the majority of its investments into the BiTAC portfolio. A key goal is to have the first BiTAC-TCE candidate, VXA-102, IND/CTA-ready by early 2028. To fund this growth, Veraxa intends to monetize selected non-BiTAC pipeline assets, including VXA-901 and a HER2-targeting ADC program, which are currently available for partnering.

Veraxa Biotech announced the initiation of cell line development for its lead BiTAC® T-cell engager (BiTAC-TCE) program. The company has partnered with ATUM, a leader in bioengineering, to utilize their proprietary Leap-In Transposase® technology for stable clonal cell line generation. This collaboration is a crucial step in advancing Veraxa's most advanced T-cell engager candidate towards IND/CTA-enabling activities and future clinical development, building on encouraging preclinical data presented at AACR. The BiTAC-TCE approach aims for greater tumor selectivity and a wider therapeutic window by requiring dual-target engagement for T-cell activation.